Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teixobactin

Next Previous
Search
Drug Profile

Teixobactin

Latest Information Update: 04 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Northeastern University; University of Bonn
  • Developer Northeastern University; NovoBiotic Pharmaceuticals; University of Bonn
  • Class Amino acids; Anti-infectives; Antibacterials; Antituberculars; Depsipeptides; Hydroxylamines; Imidazoles; Phenylpropionates; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Tuberculosis; Vancomycin-resistant enterococcal infections

Most Recent Events

  • 04 Sep 2023 Teixobactin is still in preclinical studies for Vancomycin-resistant-enterococcal-infections, Methicillin-resistant-Staphylococcus-aureus-infections, Tuberculosis, Gram-positive-infections in USA (NovoBiotic Pharmaceuticals website, September 2023)
  • 28 Aug 2020 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in USA (IV, Injection)
  • 28 Aug 2020 No recent reports of development identified for preclinical development in Vancomycin-resistant-enterococcal-infections in USA (IV, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top